Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer.
Nature Communications
Hong, Lingzhi L; Aminu, Muhammad M; Li, Shenduo S; Lu, Xuetao X; Petranovic, Milena M; Saad, Maliazurina B MB; Chen, Pingjun P; Qin, Kang K; Varghese, Susan S; Rinsurongkawong, Waree W; Rinsurongkawong, Vadeerat V; Spelman, Amy A; Elamin, Yasir Y YY; Negrao, Marcelo V MV; Skoulidis, Ferdinandos F; Gay, Carl M CM; Cascone, Tina T; Gandhi, Saumil J SJ; Lin, Steven H SH; Lee, Percy P PP; Carter, Brett W BW; Wu, Carol C CC; Antonoff, Mara B MB; Sepesi, Boris B; Lewis, Jeff J; Gibbons, Don L DL; Vaporciyan, Ara A AA; Le, Xiuning X; Jack Lee, J J; Roy-Chowdhuri, Sinchita S; Routbort, Mark J MJ; Gainor, Justin F JF; Heymach, John V JV; Lou, Yanyan Y; Wu, Jia J; Zhang, Jianjun J; Vokes, Natalie I NI
Publication Date: 2023-02-08
Variant appearance in text: PIK3CA: 2713T>A; C905S
Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.
The Journal Of Clinical Investigation
Jin, Nan N; Keam, Bhumsuk B; Cho, Janice J; Lee, Michelle J MJ; Kim, Hye Ryun HR; Torosyan, Hayarpi H; Jura, Natalia N; Ng, Patrick Ks PK; Mills, Gordon B GB; Li, Hua H; Zeng, Yan Y; Barbash, Zohar Z; Tarcic, Gabi G; Kang, Hyunseok H; Bauman, Julie E JE; Kim, Mi-Ok MO; VanLandingham, Nathan K NK; Swaney, Danielle L DL; Krogan, Nevan J NJ; Johnson, Daniel E DE; Grandis, Jennifer R JR
mTOR Signaling and SREBP Activity Increase FADS2 Expression and Can Activate Sapienate Biosynthesis.
Cell Reports
Triki, Mouna M; Rinaldi, Gianmarco G; Planque, Melanie M; Broekaert, Dorien D; Winkelkotte, Alina M AM; Maier, Carina R CR; Janaki Raman, Sudha S; Vandekeere, Anke A; Van Elsen, Joke J; Orth, Martin F MF; Grünewald, Thomas G P TGP; Schulze, Almut A; Fendt, Sarah-Maria SM